VIVE - Viveve Medical, Inc.
| Previous Close | 0.8400 |
| Open | 0.8500 |
| Bid | 0.8300 x 1000 |
| Ask | 0.8495 x 900 |
| Day's Range | 0.8300 - 0.8600 |
| 52 Week Range | 0.7900 - 135.0000 |
| Volume | 273,805 |
| Avg. Volume | 1,609,714 |
| Market Cap | 2.8M |
| Beta (5Y Monthly) | -0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -87.9270 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- ACCESSWIRE
Viveve Announces Clearance of Next Generation 2.0 System in South Korea
ENGLEWOOD, CO / ACCESSWIRE / December 10, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced registration clearance by the Korean Ministry of Food and Drug Safety for the company's next generation Viveve 2.0 cryogen-cooled monopolar radiofrequency (CMRF) system for use in general surgical procedures for electrocoagulation and hemostasis as well as for the treatment of vaginal laxity.
- ACCESSWIRE
Viveve Announces Launch of Viveve 2.0 System in China
ENGLEWOOD, CO / ACCESSWIRE / December 3, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today reported that Paragon Meditech, the Company's exclusive distribution partner in mainland China, Hong Kong and Macau, hosted a launch event for the Viveve 2.0 cryogen-cooled monopolar radiofrequency (CMRF) technology platform and products for more than 70 key opinion leader customers in Dalian, China. The comprehensive event included women's health and aesthetic practitioners from mainland China and other Asian markets across Paragon's territories and highlighted the advantages of Viveve's CMRF technology.
- ACCESSWIRE
Viveve Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
ENGLEWOOD, CO / ACCESSWIRE / November 26, 2019 / Viveve Medical, Inc. ("Viveve") (VIVE), a medical technology company focused on women's intimate health, today announced the closing of an underwritten public offering of units for gross proceeds of approximately $11.5 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Viveve. In connection with the offering, the Company's secured lender, CRG, converted $29 million of debt into a newly created series B convertible preferred stock and warrants to purchase common stock.
- Thomson Reuters StreetEvents
Edited Transcript of VIVE earnings conference call or presentation 7-Nov-19 10:00pm GMT
Q3 2019 Viveve Medical Inc Earnings Call
- ACCESSWIRE
Viveve Announces Pricing of $10 Million Underwritten Public Offering
ENGLEWOOD, CO / ACCESSWIRE / November 22, 2019 / Viveve Medical, Inc. ("Viveve") (VIVE), a medical technology company focused on women's intimate health, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $10 million prior to deducting underwriting discounts and commissions and offering expenses payable by Viveve. In connection with the offering, the Company's secured lender, CRG, has agreed to convert $29 million of senior secured notes into a newly created series B convertible preferred stock and warrants to purchase common stock.
- ACCESSWIRE
Viveve Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Company reports positive results from first full quarter of U.S. sales based on new recurring revenue model Clinical pathway for label expansion in stress urinary incontinence indications underway Company ...
- Benzinga
The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
- ACCESSWIRE
Viveve to Host Conference Call to Provide Corporate Update and Third Quarter 2019 Results on November 7, 2019
ENGLEWOOD, CO / ACCESSWIRE / October 24, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2019 financial results after the close of the U.S. financial markets on Thursday, November 7, 2019, and will host a live conference call and webcast to provide a corporate update at 5:00 PM ET the same day. A recording of the webcast will be posted on the company's investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.
- MarketWatch
Viveve Medical stock plunges toward record low after filing to sell more shares
Shave of Viveve Medical Inc. sank 9.7% toward a record low in premarket trading Friday, after the provider of health products and women's health services filed for the sale of new common stock to the public. The number of Class A common shares or Class B preferred shares the company will sell, or at what price the shares will be sold, has not yet been determined, according to a filing with the Securities and Exchange Commission. The stock has plummeted 91% over the past three months through Thursday, while the S&P 500 has eased 2.1%.
- Benzinga
Waiting For October
I hate to keep harping on this theme, but recent personal experience has shown that the new month brings a new market. And boy am I thankful that this month happens to be October. For one, September petered ...
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For October 1, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Viveve Medical (NASDAQ: VIVE ) shares were ...
- ACCESSWIRE
Viveve Raises $6.76 million Through Completion of At-The-Market Equity Financing
ENGLEWOOD, CO / ACCESSWIRE / October 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced the completion of its at-the-market (ATM) offering of $6.76 million of shares of its common stock with Ladenburg Thalmann & Co. Inc. as the sales agent. The company sold 1,004,171 shares at a weighted average price of $6.73 per share (adjusting for a reverse stock split of Viveve common stock effected September 18, 2019) resulting in net proceeds of approximately $6.56 million to the company after deduction of sales commissions. As of September 30, 2019, the company had 1,469,589 shares outstanding.
- ACCESSWIRE
Viveve Submits Investigational Testing Application to Conduct Short-Term Feasibility Study in Stress Urinary Incontinence
ENGLEWOOD, CO / ACCESSWIRE / September 19, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that it has submitted an Investigational Testing Application (ITA) to the Canadian Ministry of Health to conduct a three-arm, three-month feasibility study to compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment to cryogen-only treatment and to inert sham treatment for the improvement of stress urinary incontinence (SUI) in women. "We are pleased to announce that we have identified a strategic pathway to continue the advancement of our SUI clinical development program and pursuit of a label expansion for this indication on a global basis.
- ACCESSWIRE
Viveve and its New CEO are Pioneering Women's Intimate Health
ENGLEWOOD, CO / ACCESSWIRE / September 18, 2019 / CEOCFO Magazine, an independent investment, healthcare, and medical news publication highlights an executive change at Viveve (VIVE) in an interview (https://www.ceocfointerviews.com/interviews/Viveve19.htm) with CEO and Director, Scott Durbin. States Mr. Durbin, "As a part of the executive leadership team, beginning as CFO in 2013, I have been integral to the company's growth strategy and commercialization efforts. Viveve is at the forefront of the booming demand for clinically proven women's intimate health and wellness treatments.
- ACCESSWIRE
Viveve Announces Reverse Stock Split to Regain NASDAQ Compliance
ENGLEWOOD, CO / ACCESSWIRE / September 18, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that its Board of Directors has approved a one-for-100 reverse stock split of its common stock that is scheduled to become effective after trading closes on September 18, 2019. The company's common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis when the market opens on September 19, 2019. The company's common stock will continue to trade under the symbol "VIVE." At the company's Special Meeting of Stockholders held on September 16, 2019, the company's stockholders approved a proposal authorizing the company's Board of Directors to effect a reverse stock split in a range of 1:20 to 1:100 to help regain compliance with the Nasdaq minimum bid price requirement.
- ACCESSWIRE
Viveve to Present at the Ladenburg Thalmann 2019 Healthcare Conference
ENGLEWOOD, CO / ACCESSWIRE / September 17, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Ladenburg Thalmann 2019 Healthcare Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.
- Thomson Reuters StreetEvents
Edited Transcript of VIVE earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Viveve Medical Inc Earnings Call
- ACCESSWIRE
Viveve to Present at the H.C. Wainwright 21st Annual Global Investment Conference
ENGLEWOOD, CO / ACCESSWIRE / September 3, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the H.C. Wainwright 21st Annual Global Investment Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.
- ACCESSWIRE
Viveve Signs Exclusive Distribution Partnership with Paragon Meditech in Hong Kong, China and Macau
ENGLEWOOD, CO / ACCESSWIRE / September 3, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced an exclusive partnership agreement with Paragon Meditech Co, Ltd., a leading women’s health and medical technology distributor throughout mainland China, Hong Kong and Macau. “We are excited to partner with Paragon Meditech as we continue to expand commercial availability of the Viveve® System worldwide.
- ACCESSWIRE
Viveve Signs Exclusive Distribution Partnership in Canada with Salient Medical Solutions
ENGLEWOOD, CO / ACCESSWIRE / August 22, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced an exclusive distribution agreement with Salient Medical Solutions, a leading distributor of innovative world-class medical devices and technologies in Canada. “We are pleased to partner with Salient Medical to expand the commercial availability of the Viveve® System to physicians and healthcare providers throughout Canada,” said Scott Durbin, chief executive officer of Viveve.
- ACCESSWIRE
Viveve Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Company completed successful transition from capital sales to recurring revenue model Achieved U.S. FDA 510k and CE Mark clearances for Viveve 2.0 Expanded international distribution partnership in Middle ...
- ACCESSWIRE
Viveve Reports Additional Clinical Results of LIBERATE-International Trial for Stress Urinary Incontinence
ENGLEWOOD, CO / ACCESSWIRE / August 7, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today reported additional clinical results from the LIBERATE-International ...
- ACCESSWIRE
Viveve to Host Conference Call to Provide Corporate Update and Second Quarter 2019 Results on August 8, 2019
ENGLEWOOD, CO / ACCESSWIRE / August 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced that it will report its second quarter 2019 financial results after the close of the U.S. financial markets on Thursday, August 8, 2019, and will host a live conference call and webcast to provide a corporate update at 4:30 PM ET the same day. A recording of the webcast will be posted on the company’s investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.
- Benzinga
The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
- ACCESSWIRE
Viveve Announces Top-line Results of LIBERATE-International Trial for SUI, Q2 Transition to New U.S. Commercial Model, and Pursuit of Financial and Strategic Alternatives
ENGLEWOOD, CO / ACCESSWIRE / July 22, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today provided an update on the company’s clinical development programs and transition to a new U.S. business model, and also announced that it is conducting a review of financial and strategic alternatives. The company today announced that the LIBERATE-International trial, a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women, did not demonstrate greater improvement in SUI in treated patients as compared with the control group, and therefore did not achieve statistical significance in the intent-to-treat-population on the primary endpoint of change from baseline to six months post-treatment in the 1-hour pad weight test.